Study for Yikang Buyuan Granules in the treatment of chronic fatigue syndrome (qi deficiency and blood stasis syndrome)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900020489

Enrollment

Unknown

Registered

2019-01-02

Start date

2019-02-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic fatigue syndrome

Interventions

Case series:Yikang Buyuan Granule

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnostic criteria for chronic fatigue syndrome; (2) Comply with the syndrome differentiation standard of Chinese medicine qi deficiency and blood stasis syndrome; (3) Aged 25-60 years old male and female; (4) Voluntarily participate in this clinical trial, informed consent and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) There are primary diseases (such as malignant tumors, autoimmune diseases, infectious diseases, tuberculosis, AIDS, chronic active hepatitis, chronic inflammatory diseases, neuromuscular diseases, endocrine diseases, respiratory, circulatory and digestive diseases, etc.) can explain chronic fatigue; (2) Those with moderate to severe anxiety, depression, bipolar disorder, schizophrenia, paranoia, dementia, and anorexia nervosa; (3) Those who receive any treatment due to fatigue within 1 week before enrollment; (4) Those with primary diseases such as severe cardiovascular, cerebrovascular and hematopoietic systems; (5) ALT, AST> 1.5 times the upper limit of the normal reference value or Scr> the upper limit of the normal reference value; (6) Those who have a history of alcohol abuse and drug abuse; (7) Women who are under 1 year of delivery, pregnant or lactating women, and who are not strictly contraceptive during the trial; (8) Those who have a history of allergies to the test drug ingredients; (9) Those who have participated in other clinical trials in the past 1 month; (10) The investigator considered it inappropriate to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
VAS score of fatigue degree;	—

Secondary

Measure	Time frame
Fatigue Severity Scale (FSS) score;Physical and Mental Health Report (SPHERE) Score;Symptom evaluation of chronic fatigue syndrome;Changes of quality of life in patients;Therapeutic effect of TCM syndromes;	—

Countries

China

Contacts

Public ContactAiguo Zhou

Beijing Chinese Medicine Hospital affiliated to Capital Medical University

13911838305@163.com+86 13911838305

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026